Bank of New York Mellon
JSPR icon

Bank of New York Mellon’s Jasper Therapeutics JSPR Stock Holding History

Bank of New York Mellon’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,027
Closed -$108K – 4207
2025
Q1 		$108K Sell
25,027
-51
-0.2% -$339 ﹤0.01% 3992
2024
Q4 		$536K Buy
25,078
+1,048
+4% +$21.8K ﹤0.01% 3488
2024
Q3 		$452K Sell
24,030
-8,549
-26% -$170K ﹤0.01% 3577
2024
Q2 		$740K Buy
+32,579
New +$781K ﹤0.01% 3356
2024
Q1 		– Sell
-4,359
Closed -$34.4K – 4243
2023
Q4 		$34.4K Hold
4,359
– – ﹤0.01% 4190
2023
Q3 		$30.5K Hold
4,359
– – ﹤0.01% 4216
2023
Q2 		$59.7K Hold
4,359
– – ﹤0.01% 4149
2023
Q1 		$78.9K Buy
+4,359
New +$80.6K ﹤0.01% 4113

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bank of New York Mellon's JSPR Position: Q2 2025 in Review

Bank of New York Mellon sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 25,027 shares — an estimated $108K sold.

Bank of New York Mellon first reported a position in JSPR in Q1 2023 and held it in 8 quarters. The position peaked at $740K in Q2 2024. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • Bank of New York Mellon reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 25,027 Jasper Therapeutics shares in Q2 2025, an estimated $108K.
  • Bank of New York Mellon first reported a position in Jasper Therapeutics in Q1 2023 and held it in 8 quarters.
  • Bank of New York Mellon's Jasper Therapeutics position peaked at $740K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.